Barcelona/Darmstadt, Germany--(BUSINESS WIRE)--July 01, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.1 These figures indicate that physicians across the world are becoming increasingly aware that testing patients’ KRAS status enables them to offer each patient the treatment most likely to improve his or her therapeutic outcome.
